Transmural Remission Characterized by High Biologic Concentrations Demonstrates Better Prognosis in Crohn's Disease

Area of Science:

• Gastroenterology
• Immunology
• Radiology

Background:

• Transmural healing is crucial in Crohn's disease (CD) but its significance and pathophysiology require further investigation.
• Understanding the link between biologic drug levels and transmural remission is essential for optimizing CD treatment.

Purpose of the Study:

• To investigate the association between serum biologic concentrations and transmural remission in CD patients.
• To evaluate transmural remission as a predictor of patient prognosis compared to other remission measures.

Main Methods:

• Prospective study of 134 CD patients on maintenance biologics, followed for at least 1 year.
• Assessment of baseline laboratory, endoscopic, and magnetic resonance enterography (MRE) data.
• Analysis of relationships between baseline factors, prognosis, and serum drug concentrations versus transmural remission.

Main Results:

• Transmural remission significantly reduced the risk of hospitalization (HR 0.11) and surgery (HR 0.02) compared to other remission types.
• Patients achieving transmural remission had higher median serum concentrations for infliximab, adalimumab, and ustekinumab.
• Higher drug levels were associated with transmural remission across multiple biologic agents.

Conclusions:

• Transmural remission is the strongest predictor of prognosis in Crohn's disease patients receiving biologic therapy.
• Achieving transmural remission, confirmed by MRE, is associated with higher serum biologic drug concentrations.
• Optimizing biologic drug levels may enhance transmural healing and improve long-term outcomes in CD.